| For: | Pei WG, Chen WZ, Wu YK, Tan SX, Jie ZG. Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis. World J Gastrointest Oncol 2023; 15(2): 352-367 [PMID: 36908315 DOI: 10.4251/wjgo.v15.i2.352] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v15/i2/352.htm |
| Number | Citing Articles |
| 1 |
Jacob C. Easaw, Howard J. Lim, Hatim Karachiwala, Sharlene Gill, Xiaofu Zhu, Justin Bateman. Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options. Current Oncology 2025; 32(11) doi: 10.3390/curroncol32110648
|
| 2 |
Hyung-Don Kim, Jinho Shin, Jaewon Hyung, Hyungeun Lee, Meesun Moon, Jeongeun Ma, Young Soo Park, Min-Hee Ryu. Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression. Gastric Cancer 2025; 28(1) doi: 10.1007/s10120-024-01566-7
|
| 3 |
Hui Yuan, Miao Bao, Minqiang Chen, Junhao Fu, Shian Yu. Advances in Immunotherapy and Targeted Therapy for Gastric Cancer: A Comprehensive Review. British Journal of Hospital Medicine 2025; 86(3) doi: 10.12968/hmed.2024.0759
|
| 4 |
Xiaoxuan Ma, Wei Guo, Jialin Sun, Yanyan Liang, Chuan Yao, Yuteng Chi, Zifeng Chi, Teng Li, Ruifeng Wang, Ruiyang Gao, Yameng Gao, Ziteng Zhang, Mingchang Miao, Kai Shang, Chao Gao. Efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophagogastric junction or gastric cancer: a systematic review and meta analysis. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1745356
|